STAT Plus: Debate erupts over whether Sarepta’s rare disease drug has enough clinical data to determine cost-effectiveness
JOHN BOAL FOR THE BOSTON GLOBE
The analysis by the Institute for Clinical and Economic Review threatens to renew questions about a drug that caused debate over FDA approval standards.
.png)
No hay comentarios:
Publicar un comentario